USE CASE: Efficacy of Immunospuressants
Arbor Research Collaborative for Health conducts major studies in epidemiology and public health. They collaborate closely with faculty and researchers from other major research organizations in the United States and around the world to perform research that affects clinical practice, policy development, and medical payment systems. Since 1997, they have engaged in national and international health outcomes research related to chronic disease and end-stage organ failure.
Project Summary: Immunosuppressant medications prevent transplant recipients from rejecting their new organs. FDA-approved versions of generic immunosuppressant medications are now available. Arbor Research used CO APCD data to estimate the proportions of generic and brand name immunosuppressant medications dispensed over time. The Study was funded by a grant from the FDA. This research aims to elucidate patterns of generic adoption and investigate the implications of generic substitution.
Benefit to Colorado: These analyses highlighted trends in prescriptions dispensed for generic and brand name immunosuppressant medications among transplant recipients. Arbor Research was able to document the trend in generic drug prescriptions shortly after the approval of each drug. Moving forward, the results of this project could inform efforts to improve care for transplant patients in Colorado and across the nation. Click here to view results of this analysis.